Regeneron Pharmaceuticals, Inc

Biotechnology

REGN

$ 801 0.38

Share price

$ 87 bn

Market Cap

$ 78 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.03x the weighted average for S&P 500

FY2021

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Regeneron Pharmaceuticals, Inc reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 92 Kt (+11/+14% y-o-y). At the sime time, carbon intensity tumbled to 5.7 t (-3.8 /-40% y-o-y).

Regeneron Pharmaceuticals, Inc's Scope 3 emissions grew to 822 Kt (+53/+6.9% y-o-y). The growth rate declined vs. the previous periods (CAGR +24% since 4Q'17).

The company has not set a company-wide target for an absolute reduction in GHG emissions yet.

Date	Total CO2e emissions (market-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2021Q4	92	65	27	822	16,072	5.7
2020Q4	81	58	23	769	8,497	9.5
2019Q4	80	58	23	560	6,558	12
2018Q4	86	58	28	395	6,711	13
2017Q4	88	49	40	284	5,872	15
2016Q4	65	39	25	289	4,860	13

Regeneron Pharmaceuticals, Inc

Carbon footprint

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Regeneron Pharmaceuticals, Inc's carbon footprint

Company environmental metrics